Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4138853 | 0.83 | AR (0.74) | ARLMNA | |
| SCHEMBL4138480 | 0.81 | AR (0.62) | ARLMNA | |
| SCHEMBL4130936 | 0.79 | AR (0.56) | ARMALT1 | |
| SCHEMBL17416811 | 0.78 | AR (0.53) | ARLMNAMAPTMAPK14TNKS2 | |
| SCHEMBL17416810 | 0.78 | AR (0.53) | ARLMNAMAPTTNKS2TP53 | |
| SCHEMBL4142951 | 0.76 | AR (0.71) | ARLMNAPDPK1 | |
| SCHEMBL4131580 | 0.75 | AR (0.51) | ARLMNAMAPTTNKS2TP53 | |
| SCHEMBL4147947 | 0.75 | AR (0.77) | ARLMNA | |
| SCHEMBL31584718 | 0.75 | AR (1.00) | ARLMNA | |
| SCHEMBL4130914 | 0.75 | AR (1.00) | ARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580811-B2 | Androgen receptor modulator methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165362-A1 | Androgen receptor modulator compounds and methods | AR, NR5A1, ESRRA | AR 1/4885LMNA 3994/4885MAPT 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.